Recent
Mass General Brigham scientists unveil a blood test, HPV-DeepSeek, that identifies HPV-related head and neck cancers up to a decade before symptoms, demonstrating unmatched sensitivity and specificity in NIH-backed studies.
October 14, 2025
Source:
SciTechDaily
Early Cancer Detection with New Blood Test
Researchers at Mass General Brigham have developed HPV-DeepSeek, a revolutionary blood test that can identify HPV-linked head and neck cancers up to ten years before clinical diagnosis. Unlike current methods, this test detects viral DNA fragments from HPV in the bloodstream long before symptoms appear.
Background
Human Papillomavirus (HPV) causes about 70% of head and neck cancers in the U.S., mostly oropharyngeal cancers. There are established screening programs for cervical cancer, but none have existed for these rapidly increasing cancers of the head and neck, leading to frequently late diagnoses.
No approved screening for early HPV-related head and neck cancers.
Most cases are detected after tumors become large and symptomatic.
For more details, see the Mass General Brigham press release.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Mass General Brigham
How the Test Works and Its Performance
HPV-DeepSeek uses whole-genome sequencing technology, analyzing blood samples for traces of HPV DNA shed by tumor cells. The technology was tested retrospectively on blood samples from 56 individuals—28 who developed HPV-related cancer and 28 who did not. The test detected DNA signals in samples taken as early as 10 years prior to clinical diagnosis.
Key Findings
Identified HPV DNA in 22 of 28 pre-diagnosis samples.
Machine learning improved detection to 27 of 28 cases.
No false positives among controls.
Sensitivity: 99% | Specificity: 99%
This performance outstrips current blood-based screening methods, and ScienceDaily provides visual summaries and further explanation.
Read More
Source:
Harvard Gazette
Next Steps and Future Impact
The findings are now undergoing large-scale validation in a blinded National Institutes of Health (NIH) trial. Researchers hope, if validated, HPV-DeepSeek could become the first population screening tool for oropharyngeal cancers—mirroring the impact of Pap smears on cervical cancer prevention.
Implications
Early detection: Allows less invasive, more effective treatments.
Improved survival rates: Potential to dramatically raise survival rates and reduce the need for aggressive therapies.
May serve as a model for other virus-linked cancers.
Principal investigator Dr. Daniel L. Faden and team emphasize the test’s transformative potential for patient care and public health. For more, see the press release.
How does HPV-DeepSeek compare to other liquid biopsy tests?
HPV-DeepSeek offers superior sensitivity and specificity (99% each) for early HPV-related cancer detection, outperforming current blood-based and liquid biopsy methods which typically provide lower accuracy.
What are the potential side effects of the treatments made possible by HPV-DeepSeek?
How widely available is the HPV-DeepSeek test currently?
What are the next steps for the NIH trial of HPV-DeepSeek?
How does HPV-DeepSeek work at the molecular level?
Share this news:
